The challenge of viral reservoirs in hiv-1 infection

Annual Review of Medicine

Volumn 53, Issue , 2002, Pages 557-593

  Blankson, Joel N ^a   Persaud, Deborah ^a   Siliciano, Robert F ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS; HAART; Latency; Persistence; Sanctuary

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD4 CD3 FUSION PROTEIN; CD8 ANTIGEN; EFAVIRENZ; HYBRID PROTEIN; INTERLEUKIN 2; LAMIVUDINE; LOPINAVIR; OKT 3; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; B LYMPHOCYTE; CENTRAL NERVOUS SYSTEM; DENDRITIC CELL; GENE EXPRESSION; HALF LIFE TIME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; LATENT PERIOD; LYMPHOID ORGAN; MACROPHAGE; MEMORY CELL; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; UROGENITAL SYSTEM; VIRUS CARRIER; VIRUS EXCRETION; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE;

ANIMALS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV-1; HUMANS; VIRUS LATENCY; VIRUS REPLICATION;

EID: 0036176509     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.53.082901.104024     Document Type: Review

References (206)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
3. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
4. Decay characteristics of HIV-1-infected compartments during combination therapy
5. Rational approach to AIDS drug design through structural biology
6. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
7. Immune reconstitution in patients with HIV infection
8. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
9. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
10. HIV chemotherapy
11. Quantitation of latent tissue reservoirs and total body load in HIV-1 infection
12. Fate of HIV-1-infected T cells in vivo: Rates of transition to stable latency
13. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
14. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
15. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
16. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
17. A stable latent reservoir for HIV-1 in resting CD4+ T lymphocytes in infected children
18. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy
19. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
20. Persistence of HIV- 1 transcription in peripheral blood mononuclear cells in patients receiving potent antiretroviral therapy
21. Persistence of episomal HIV- 1 infection intermediates in patients on highly active anti-retroviral therapy
22. Time of initiation of antiretroviral therapy: Impact on HIV-1 viraemia. The Swiss HIV Cohort study
23. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR
24. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
25. Viral dynamics in human immunodeficiency virus type 1 infection
26. HIV-1 dynamics in vivo: Virion clearance rate, infected cell lifespan, viral generation time
27. Rapid clearance of simian immunodeficiency virus particles from plasma of rhesus macaques
28. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells
29. Fidelity of HIV-1 reverse transcriptase
30. The accuracy of reverse transcriptase from HIV-1
31. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
32. Dynamics of HIV-1 and CD4+ lymphocytes in vivo
33. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
34. Kinetics of response in lymphoid tissue to antiretroviral therapy of HIV-1 infection
35. Dynamics of human immunodeficiency virus type 1 replication in vertically infected infants
36. Infection of monocyte/macrophages by human T lymphotropic virus type III
37. In vitro infection of human monocytes with T lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV)
38. Origin and turnover of monocytes and macrophages
39. Relationship between load of virus in alveolar macrophages from human immunodeficiency virus type 1-infected persons, production of cytokines, and clinical status
40. Low infection frequency of macrophages in the spleens of HIV+ patients
41. Macrophages as a source of HIV during opportunistic infections
42. Macrophages are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans
43. Lymphoid germinal centers are reservoirs of human immunodeficiency virus type 1 RNA
44. Simian immunodeficiency virus-specific CD8+ lymphocyte response in acutely infected rhesus monkeys
45. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS
46. Follicular dendritic cells (FDC) in retroviral infection: Host/pathogen perspectives
47. Role of dendritic and follicular dendritic cells in HIV infection and pathogenesis
48. A new approach to investigating the relationship between productive infection and cytopathicity in vivo
49. Follicular dendritic cells and human immunodeficiency virus infectivity
50. Persistence of infectious HIV on follicular dendritic cells
51. Dissociation of HIV-1 from follicular dendritic cells during HAART: Mathematical analysis
52. Influence of follicular dendritic cells on decay of HIV during antiretroviral therapy
53. Loss of envelope antigens of HTLV-III/LAV, a factor in AIDS pathogenesis
54. Shedding and interspecies type sero-reactivity of the envelope glycopolypeptide gp120 of the human immunodeficiency virus
55. Dissociation of gp120 from HIV-1 virions induced by soluble CD4
56. Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: Effects on infectivity and neutralization
57. AIDS virus-specific cytotoxic T lymphocytes in lung disorders
58. HIV-specific cytotoxic T lymphocytes in seropositive individuals
59. Cytotoxic T lymphocytes in human immunodeficiency virus infection: Responses to structural proteins
60. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
61. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors
62. Dramatic rise in plasma viremia after CD8+ T cell depletion in simian immunodeficiency virus-infected macaques
63. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes
64. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia
65. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection
66. Reservoirs for HIV-I: Mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy
67. Immunological memory and protective immunity: Understanding their relation
68. Counting antigen-specific CD8 T cells: A reevaluation of bystander activation during viral infection
69. Amplification of HTLV-III/LAV infection by antigen-induced activation of T cells and direct suppression by virus of lymphocyte blastogenic responses
70. Characterization of chemokine receptor utilization of viruses in the latent reservoir for HIV-1
71. Expression patterns of the HIV type 1 coreceptors CCR5 and CXCR4 on CD4+ T cells and monocytes from cord and adult blood
72. + T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4(+) T cell decline
73. LAI
74. HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure
75. Incompletely reverse-transcribed human immunodeficiency virus type I genomes function as intermediates in the retroviral life cycle
76. Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells
77. Nonproductive human immunodeficiency virus type 1 infection in nucleoside-treated G0 lymphocytes
78. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection
79. Active nuclear import of human immunodeficiency virus type 1 preintegration complexes
80. Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro
81. Biphasic decay of latently infected CD4+ T cells in acute HIV- 1 infection
82. An inducible transcription factor activates expression of human immunodeficiency virus in T cells
83. Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat
84. Lifespan of human lymphocyte subsets defined by CD45 isoforms
85. In vivo estimates of division and death rates of human T lymphocytes
86. The decay of the latent reservoir of replication competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged antiretroviral therapy
87. Efficient replication of human immunodeficiency virus type 1 requires a threshold level of Rev: Potential implications for latency
88. Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: A molecular model for latency
89. Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection
90. HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor
91. Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir
92. Recovery of replication-competent virus from CD4 T cell reservoirs and change in coreceptor use in human immunodeficiency virus type 1-infected children responding to highly active antiretroviral therapy
93. Control of HIV despite the discontinuation of antiretroviral therapy
94. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression
95. Genetic characterization of rebounding HIV- 1 after cessation of highly active antiretroviral therapy
96. Relationship between preexisting viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy
97. Immune control of HIV-1 after early treatment of acute infection
98. Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy
99. Latency and viral persistence in HIV-1 infection
100. Persistence of memory CD8 T cells in MHC class I-deficient mice
101. Longitudinal analysis of acute Sendai virus-specific CD4+ T cell response and memory
102. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C
103. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple drug therapy
104. Trilege study team: A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously treated patients
105. Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA
106. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy
107. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy
108. Antiretroviral resistance during successful therapy of human immunodeficiency virus type 1 infection
109. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia
110. HIV-1 drug resistance profiles in children and adults with viral load <50 copies/mL receiving combination therapy
111. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
112. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase
113. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase
114. Antiretroviral intensification accelerates the decay of the latent reservoir of HIV-1 and decreases but does not eliminate ongoing virus replication
115. Latent reservoir and residual HIV-1 replication on antiretroviral therapy
116. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy
117. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy
118. A randomized, controlled pilot study of HAART versus HAART plus IL-2 for the treatment of recently acquired HIV infection
119. Kinetics of productive and latent HIV infection in lymphatic tissue and peripheral blood during triple-drug combination therapy with or without additional interleukin-2
120. Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission
121. Vigorous HIV-1-specific CD4+ T cell responses associated with the control of viremia
122. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression
123. Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption
124. Structured treatment interruptions to control HIV-1 infection
125. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy
126. + T cells in human immunodeficiency virus-infected subjects
127. Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors
128. Sexual transmission and propagation of SIV and HIV-1 in activated and quiescent T cells
129. Preferential infection of CD4+ memory T cells by human immunodeficiency virus type 1: Evidence for a role in the selective T-cell functional defects observed in infected individuals
130. CD4+ memory T cells are the predominant population of HIV-1-infected lymphocytes in neonates and children
131. + T cells are infected in human immunodeficiency virus type 1-infected individuals
132. Generation of HIV latency during thymopoiesis
133. Alternative targets of productive HIV infection: Role of CD4 up-regulation on susceptibility of cells to HIV infection
134. Frequent infection of peripheral blood CD8-posifive T lymphocytes
135. + lymphocytes induces CD4 expression and allows human immunodeficiency virus type 1 infection
136. Productive infection of neonatal CD8+ T lymphocytes by HIV-1
137. Activation of CD8+ T lymphocytes through the T cell receptor turns on CD4 gene expression: Implications for HIV pathogenesis
138. Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy
139. HIV-1 genotypes in peripheral blood monocytes
140. Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy
141. B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells
142. Conjugates of dendritic cells and memory T lymphocytes from skin facilitate productive infection with HIV-1
143. + T cells
144. Replication of HIV-1 in dendritic cell-derived syncytia at the mucosal surface of the adenoid
145. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells
146. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease
147. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection
148. Residual human immunodeficiency virus (HIV) type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years
149. Visualising the generation of memory T cells in the whole body
150. HIV-1-induced thymocyte depletion is associated with indirect cytopathicity and infection of progenitor cells in vivo
151. CD8 naive T cell counts decrease progressively in HIV-infected adults
152. Altered representation of naive and memory CD8 T cell subsets in HIV-infected children
153. + T cell homeostasis and function in advanced HIV disease
154. High prevalence of thymic tissue in adults with human immunodeficiency virus-1 infection
155. Changes in thymic function with age and during the treatment of HIV infection
156. Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy
157. Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection
158. Temporal trends in the incidence of HIV-1 related neurologic diseases: Multicenter AIDS Cohort Study, 1985-1992
159. Human immunodeficiency virus and the brain
160. Simian immunodeficiency virus burden in tissues and cellular compartments during clinical latency and AIDS
161. SIV infection of macaques - Modeling the progression to AIDS dementia
162. Localization of HIV-1 in human brain using polymerase chain reaction/in situ hybridization and immunocytochemistry
163. The role of mononuclear phagocytes in HTLV-III/LAV infection
164. Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: Definition of critical amino acids involved in cell tropism
165. HIV-1 latency due to the site of proviral integration
166. Comparison of human immunodeficiency virus biological phenotypes isolated from cerebrospinal fluid and peripheral blood
167. HIV infection of the central nervous system is characterized by rapid turnover of viral RNA in cerebrospinal fluid
168. Effect of genotypic resistance on the virological response to highly active antiretroviral therapy in cerebrospinal fluid
169. Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources
170. Productive human immunodeficiency virus type 1 (HIV-1) infection of nonproliferating human monocytes
171. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine
172. Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1-infected patients with and without AIDS dementia complex
173. Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir
174. The functional role of P-glycoprotein in the blood-brain barrier
175. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter
176. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
177. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor
178. In vivo evidence for carrier-mediated efflux transport of 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine across the blood-brain barrier via a probenecid-sensitive transport system
179. Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid
180. Independent HIV replication in paired CSF and blood viral isolates during antiretroviral therapy
181. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples
182. Central nervous system (CNS) as sanctuary of HIV-1 in a patient treated with AZT+3TC+indinavir
183. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy
184. HIV-1-related neurological disease incidence changes in the era of highly active antiretroviral therapy
185. Differential effect of HAART on development of opportunistic illness and death in clinical practice
186. Safety and efficacy of abacavir (ABC, 1592) in AIDS dementia complex (Study CNAB 3001)
187. Regression of HIV encephalopathy and basal ganglia signal intensity abnormality at MR imaging in patients with AIDS after the initiation of protease inhibitor therapy
188. Combination antiretroviral therapy including protease inhibitors improves HIV-associated cognitive impairment
189. T lymphocytes and macrophages, but not motile spermatozoa, are a significant source of human immunodeficiency virus in semen
190. In situ detection of PCR-amplified HIV-1 nucleic acids and tumor necrosis factor cDNA in cervical tissues
191. Human immunodeficiency virus (HIV) infection of the uterine cervix
192. Detection of HIV p17 antigen in lymphocytes but not epithelial cells from cervicovaginal secretions of women seropositive for HIV: Implications for heterosexual transmission of the virus
193. Human immunodeficiency virus in semen arises from a genetically distinct virus reservoir
194. Detection and biologic characterization of infectious HIV-1 in semen of seropositive men
195. Antiretroviral drug concentrations in semen of HIV-1 infected men
196. Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy
197. Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: Implications for transmission
198. Detection of drug resistance mutations in the human immunodeficiency virus type 1 (HIV-1) pol gene: Differences in semen and blood HIV-1 RNA and proviral DNA
199. HIV-1 in semen: An isolated virus reservoir
200. HIV-1 in the semen of men receiving highly active anti-retroviral therapy
201. Multiple drug resistance mutations in human immunodeficiency virus in semen but not blood of a man on antiretroviral therapy
202. Renal epithelium is a previously unrecognized site of HIV-1 infection
203. HIV-1 kills renal tubular epithelial cells in vitro by triggering an apoptotic pathway involving caspase activation and Fas upregulation
204. Chemokine receptor (CCR5) expression in human kidneys and in the HIV infected macaque